Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24112040 | 0.92 | ERBB2 (0.61) | ERBB2MINK1ADRB2CA9ALOX5 | |
| SCHEMBL26316712 | 0.90 | ERBB2 (0.49) | ERBB2MINK1ADRB2TYRCA9 | |
| SCHEMBL26316711 | 0.88 | ERBB2 (0.53) | ERBB2MINK1ADRB2TYRCA9 | |
| SCHEMBL26316562 | 0.85 | ERBB2 (0.57) | ERBB2MINK1ADRB2TYRCA9 | |
| SCHEMBL26316569 | 0.85 | ERBB2 (0.56) | ERBB2MINK1ADRB2TYRCA9 | |
| SCHEMBL22397930 | 0.84 | ERBB2 (0.49) | ERBB2MINK1ADRB2HDAC1EP300 | |
| SCHEMBL28481977 | 0.84 | ERBB2 (0.49) | ERBB2MINK1ADRB2HDAC1EP300 | |
| SCHEMBL26316571 | 0.83 | ERBB2 (0.56) | ERBB2MINK1ADRB2TYRCA9 | |
| SCHEMBL26316840 | 0.82 | ERBB2 (0.54) | ERBB2MINK1ADRB2TYRCA9 | |
| SCHEMBL24112023 | 0.82 | ERBB2 (0.60) | ERBB2MINK1ADRB2CA9HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, IDH1 | ERBB2 2558/4885MINK1 1781/4885ADRB2 4491/4885 |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, NUTF2 | ERBB2 2443/4885MINK1 1986/4885ADRB2 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.